Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma

Cheng Lung Hsu; Kai Ping Chang; Chien Yu Lin; Hsien Kun Chang; Cheng Hsu Wang; Tung Liang Lin; Chun Ta Liao; Ngan Ming Tsang; Li Yu Lee; Sheng Chieh Chan; Shu Hang Ng; Hsin Pai Li; Yu Sun Chang; Hung Ming Wang

doi:10.1002/hed.21890

Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma

Cheng Lung Hsu, Kai Ping Chang, Chien Yu Lin, Hsien Kun Chang, Cheng Hsu Wang, Tung Liang Lin, Chun Ta Liao, Ngan Ming Tsang, Li Yu Lee, Sheng Chieh Chan, Shu Hang Ng, Hsin Pai Li, Yu Sun Chang, Hung Ming Wang^*

^*Corresponding author for this work

Chang Gung University

Research output: Contribution to journal › Journal Article › peer-review

58 Scopus citations

Abstract

Background To investigate the pretreatment copy number and the clearance rate of plasma Epstein-Barr virus (EBV) DNA as novel prognostic outcome markers for metastatic nasopharyngeal carcinoma (NPC). Methods Seventy-three patients with metastatic NPC were treated at outpatient department. Plasma EBV DNA concentrations and half-life values of plasma viral clearance rates, were determined by real-time quantitative polymerase chain reaction. Results Treatment response evaluated after 3 to 6 months of treatment showed that the overall response rate was 53.5%. The pretreatment plasma EBV DNA concentrations and the half-life of plasma EBV DNA clearance rates had significant effects on treatment response and overall survival prediction. In the chemotherapy regimen, gemcitabine plus cisplatin had a better treatment outcome than the cisplatin plus oral UFT and calcium folinate-based regimens. Conclusions The pretreatment plasma EBV DNA copy number and their clearance rates are significant predictors for NPC treatment outcome. © 2011 Wiley Periodicals, Inc. Head Neck, 2012

Original language	English
Pages (from-to)	1064-1070
Number of pages	7
Journal	Head and Neck
Volume	34
Issue number	8
DOIs	https://doi.org/10.1002/hed.21890
State	Published - 08 2012

Keywords

DNA
chemotherapy
epstein-barr virus
head and neck cancer
nasopharyngeal cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.21890

Cite this

Hsu, C. L., Chang, K. P., Lin, C. Y., Chang, H. K., Wang, C. H., Lin, T. L., Liao, C. T., Tsang, N. M., Lee, L. Y., Chan, S. C., Ng, S. H., Li, H. P., Chang, Y. S., & Wang, H. M. (2012). Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head and Neck, 34(8), 1064-1070. https://doi.org/10.1002/hed.21890

@article{46fdaced044f4fb992085bca36e90965,

title = "Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma",

abstract = "Background To investigate the pretreatment copy number and the clearance rate of plasma Epstein-Barr virus (EBV) DNA as novel prognostic outcome markers for metastatic nasopharyngeal carcinoma (NPC). Methods Seventy-three patients with metastatic NPC were treated at outpatient department. Plasma EBV DNA concentrations and half-life values of plasma viral clearance rates, were determined by real-time quantitative polymerase chain reaction. Results Treatment response evaluated after 3 to 6 months of treatment showed that the overall response rate was 53.5\%. The pretreatment plasma EBV DNA concentrations and the half-life of plasma EBV DNA clearance rates had significant effects on treatment response and overall survival prediction. In the chemotherapy regimen, gemcitabine plus cisplatin had a better treatment outcome than the cisplatin plus oral UFT and calcium folinate-based regimens. Conclusions The pretreatment plasma EBV DNA copy number and their clearance rates are significant predictors for NPC treatment outcome. {\textcopyright} 2011 Wiley Periodicals, Inc. Head Neck, 2012",

keywords = "DNA, chemotherapy, epstein-barr virus, head and neck cancer, nasopharyngeal cancer",

author = "Hsu, \{Cheng Lung\} and Chang, \{Kai Ping\} and Lin, \{Chien Yu\} and Chang, \{Hsien Kun\} and Wang, \{Cheng Hsu\} and Lin, \{Tung Liang\} and Liao, \{Chun Ta\} and Tsang, \{Ngan Ming\} and Lee, \{Li Yu\} and Chan, \{Sheng Chieh\} and Ng, \{Shu Hang\} and Li, \{Hsin Pai\} and Chang, \{Yu Sun\} and Wang, \{Hung Ming\}",

year = "2012",

month = aug,

doi = "10.1002/hed.21890",

language = "英语",

volume = "34",

pages = "1064--1070",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley \& Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma

AU - Hsu, Cheng Lung

AU - Chang, Kai Ping

AU - Lin, Chien Yu

AU - Chang, Hsien Kun

AU - Wang, Cheng Hsu

AU - Lin, Tung Liang

AU - Liao, Chun Ta

AU - Tsang, Ngan Ming

AU - Lee, Li Yu

AU - Chan, Sheng Chieh

AU - Ng, Shu Hang

AU - Li, Hsin Pai

AU - Chang, Yu Sun

AU - Wang, Hung Ming

PY - 2012/8

Y1 - 2012/8

N2 - Background To investigate the pretreatment copy number and the clearance rate of plasma Epstein-Barr virus (EBV) DNA as novel prognostic outcome markers for metastatic nasopharyngeal carcinoma (NPC). Methods Seventy-three patients with metastatic NPC were treated at outpatient department. Plasma EBV DNA concentrations and half-life values of plasma viral clearance rates, were determined by real-time quantitative polymerase chain reaction. Results Treatment response evaluated after 3 to 6 months of treatment showed that the overall response rate was 53.5%. The pretreatment plasma EBV DNA concentrations and the half-life of plasma EBV DNA clearance rates had significant effects on treatment response and overall survival prediction. In the chemotherapy regimen, gemcitabine plus cisplatin had a better treatment outcome than the cisplatin plus oral UFT and calcium folinate-based regimens. Conclusions The pretreatment plasma EBV DNA copy number and their clearance rates are significant predictors for NPC treatment outcome. © 2011 Wiley Periodicals, Inc. Head Neck, 2012

AB - Background To investigate the pretreatment copy number and the clearance rate of plasma Epstein-Barr virus (EBV) DNA as novel prognostic outcome markers for metastatic nasopharyngeal carcinoma (NPC). Methods Seventy-three patients with metastatic NPC were treated at outpatient department. Plasma EBV DNA concentrations and half-life values of plasma viral clearance rates, were determined by real-time quantitative polymerase chain reaction. Results Treatment response evaluated after 3 to 6 months of treatment showed that the overall response rate was 53.5%. The pretreatment plasma EBV DNA concentrations and the half-life of plasma EBV DNA clearance rates had significant effects on treatment response and overall survival prediction. In the chemotherapy regimen, gemcitabine plus cisplatin had a better treatment outcome than the cisplatin plus oral UFT and calcium folinate-based regimens. Conclusions The pretreatment plasma EBV DNA copy number and their clearance rates are significant predictors for NPC treatment outcome. © 2011 Wiley Periodicals, Inc. Head Neck, 2012

KW - DNA

KW - chemotherapy

KW - epstein-barr virus

KW - head and neck cancer

KW - nasopharyngeal cancer

UR - https://www.scopus.com/pages/publications/84864278288

U2 - 10.1002/hed.21890

DO - 10.1002/hed.21890

M3 - 文章

C2 - 22083949

AN - SCOPUS:84864278288

SN - 1043-3074

VL - 34

SP - 1064

EP - 1070

JO - Head and Neck

JF - Head and Neck

IS - 8

ER -

Plasma epstein-barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this